Brief: AIM Vaccine Says MRNA COVID-19 Vaccine Candidates Got Clinical Trial Approvals In Pakistan
15/02/2023 15:04
Feb 15 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* MRNA COVID-19 VACCINE CANDIDATES AGAINST COVID-19-
VARIANTS AND
ORIGINAL STRAIN GOT CLINICAL- TRIAL APPROVALS IN PAKISTAN
* CO'S MRNA COVID-19 VACCINE CANDIDATE AGAINST ORIGINAL
COVID-19
STRAIN APPROVED TO BEGIN PHASE III TRIALS IN PAKISTAN
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine